Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.

PloS one - 1 Jan 2015

Penttinen Kirsi, Swan Heikki, Vanninen Sari, Paavola Jere, Lahtinen Annukka M, Kontula Kimmo, Aalto-Setälä Katriina

Abstract excerpt

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inherited arrhythmogenic disorder. Type 1 CPVT (CPVT1) is caused by cardiac ryanodine receptor (RyR2) gene mutations resulting in abnormal calcium release from sarcoplasmic reticulum. Dantrolene, an inhibitor of sarcoplasmic Ca(2+) release, has been shown to rescue this abnormal Ca(2+) release in vitro. We assessed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Arrhythmias, Cardiac

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epinephrine

Share to Induced Pluripotent Stem Cells

Share to Myocytes, Cardiac

Share to Polymorphic Catecholaminergic Ventricular Tachycardia

Share to Ryanodine Receptor Calcium Release Channel

Share to Tachycardia, Ventricular

Source

Open in PubMed Open full text

Identifiers

PMID: 25955245
DOI: 10.1371/journal.pone.0125366
PMCID: PMC4425399

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.PMID 25955245Read ↗

Dantrolene rescues arrhythmogenic RYR2 defect in a patient‐specific stem cell model of catecholaminergic polymorphic ventricular tachycardiaSemantic proximity Read ↗

Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.Semantic proximity Read ↗

A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responsesSemantic proximity Read ↗

Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.Semantic proximity Read ↗

CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.Semantic proximity Read ↗

Molecular and Electrophysiological Bases of Catecholaminergic Polymorphic Ventricular TachycardiaSemantic proximity Read ↗

Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.Semantic proximity Read ↗

Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.Semantic proximity Read ↗

Efficacy of RyR2 inhibitor EL20 in induced pluripotent stem cell‐derived cardiomyocytes from a patient with catecholaminergic polymorphic ventricular tachycardiaSemantic proximity Read ↗

Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.Semantic proximity Read ↗

Catecholaminergic Polymorphic Ventricular Tachycardia.Semantic proximity Read ↗

A Novel Mice Model of Catecholaminergic Polymorphic Ventricular Tachycardia Generated by CRISPR/Cas9Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.